Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Read More
Athersys begins clinical trial for MultiStem cell therapy for COVID-19
Athersys announced that it has begun enrollment in its phase II/III study named MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome. Read More
COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the novel coronavirus. In a new article, Ivan Gandayuwana of Strategic Directions International examines the multiple impacts COVID-19 is having on pharma. Read More
Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene therapy, according to a new review article published April 24 in Frontiers in Microbiology. Read More
Fujifilm Diosynth partners with Oxgene for gene therapy
Fujifilm Diosynth Biotechnologies has partnered with Oxgene to deliver gene therapy products with a 25% reduction in production time, the company reported on April 23. Read More
MilliporeSigma expands viral and gene therapy capacity
MilliporeSigma is expanding its BioReliance viral and gene therapy service offering with a second commercial manufacturing facility in Carlsbad, CA. The $110 million facility is set to open in 2021. Read More
Biolytic unveils DNA, RNA synthesizer
Biolytic Lab Performance has introduced Dr. Oligo 768XLc, a DNA and RNA synthesis platform. Read More
Directed evolution shows promise in reducing drug discovery times
A research collaboration between scientists at the University of Leeds and AstraZeneca resulted in the development of a technique that can significantly reduce the discovery time for possible new antibody-based therapies. The approach, published in Nature Communications on April 14, shows how protein fragments can be screened for susceptibility to aggregation in early drug discovery. Read More
Ori Biotech, Achilles to test manufacturing processes
Cell and gene therapy manufacturing firm Ori Biotech has partnered with biopharmaceutical company Achilles Therapeutics to test Ori's manufacturing technology in Achilles' manufacturing process. Read More
ThermoGenesis to develop COVID-19 therapeutics
ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics for COVID-19. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter